Sugapriya Dhanasekaran, Shanthi Palanivelu, Sachdanandam Panchanatham
Department of Pathology, Dr. A.L.M. Post-Graduate Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai 113, Tamil Nadu, India.
Chem Biol Interact. 2008 May 9;173(1):43-58. doi: 10.1016/j.cbi.2008.01.013. Epub 2008 Feb 15.
Chronic myeloid leukemia (CML) is a clonal disorder characterized by proliferation of hematopoietic cells that possess the BCR-ABL fusion gene resulting in the production of a 210 kDa chimeric tyrosine kinase protein. CML, when left untreated, progresses to a blast phase during which the disease turns aggressive and shows poor response to known treatment regimens. We have studied a Siddha herbal agent, Semecarpus anacardium Linn. nut milk extract (SA) for its antileukemic activity and its effect on the changes in energy metabolism in leukemic mice. Leukemia was induced in BALB/c mice by tail vein injection of BCR-ABL(+) 12B1 murine leukemia cell line. This resulted in an aggressive leukemia, similar to CML in blast crisis, myeloid subtype, confirmed by histopathological study and RT-PCR for the p210 mRNA in the peripheral blood, spleen and liver. Leukemia-bearing mice showed a significant increase in lipid peroxides, glycolytic enzymes, a decrease in gluconeogenic enzymes and significant decrease in the activities of TCA cycle and respiratory chain enzymes as compared to control animals. SA treatment was compared with standard drug imatinib mesylate. SA administration to leukemic animals resulted in clearance of the leukemic cells from the bone marrow and internal organs on histopathological examination and this was confirmed by RT-PCR for the p210 mRNA. Treatment with SA significantly reversed the changes seen in the levels of the lipid peroxides, the glycolytic enzymes, the gluconeogenic enzymes and the mitochondrial enzymes. These effects are probably due to the flavonoids, polyphenols and other compounds present in SA which result in total regression of leukemia and correction of the alterations in energy metabolism. Study of animals treated with SA alone did not reveal any adverse effects. On the basis of the observed results, SA can be considered as a readily accessible, promising and novel antileukemic chemotherapeutic agent.
慢性粒细胞白血病(CML)是一种克隆性疾病,其特征是具有BCR-ABL融合基因的造血细胞增殖,导致产生一种210 kDa的嵌合酪氨酸激酶蛋白。未经治疗的CML会进展为急变期,在此期间疾病变得具有侵袭性,并且对已知治疗方案反应不佳。我们研究了一种印度传统草药制剂——印度没药树坚果乳提取物(SA)的抗白血病活性及其对白血病小鼠能量代谢变化的影响。通过尾静脉注射BCR-ABL(+) 12B1小鼠白血病细胞系,在BALB/c小鼠中诱导白血病。这导致了一种侵袭性白血病,类似于急变期的CML髓系亚型,经组织病理学研究和外周血、脾脏及肝脏中p210 mRNA的逆转录聚合酶链反应(RT-PCR)证实。与对照动物相比,荷瘤小鼠的脂质过氧化物、糖酵解酶显著增加,糖异生酶减少,三羧酸循环(TCA)和呼吸链酶的活性显著降低。将SA治疗与标准药物甲磺酸伊马替尼进行比较。对白血病动物给予SA后,组织病理学检查显示白血病细胞从骨髓和内脏清除,这通过p210 mRNA的RT-PCR得到证实。SA治疗显著逆转了脂质过氧化物、糖酵解酶、糖异生酶和线粒体酶水平的变化。这些作用可能归因于SA中存在的黄酮类、多酚类和其他化合物,它们导致白血病完全消退并纠正能量代谢的改变。单独用SA治疗动物的研究未发现任何不良反应。基于观察结果,SA可被视为一种易于获取、有前景的新型抗白血病化疗药物。